Literature DB >> 17052817

Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene.

Xizhong Zhang1, Maziar Divangahi, Patricia Ngai, Michael Santosuosso, James Millar, Anna Zganiacz, Jun Wang, Jonathan Bramson, Zhou Xing.   

Abstract

Plasmid DNA vaccine has been widely explored for tuberculosis immunization but there is a need to develop the ways to improve its immunogenicity. In this study, we have constructed a plasmid DNA vaccine coding for Ag85A alone or for both Ag85A and GM-CSF and investigated the immune adjuvant effects of electroporation and GM-CSF co-expression, alone or in combination, on CD4 and CD8 T cell IFN-gamma responses, CTL activities and immune protection from pulmonary Mycobacterium tuberculosis challenge in a Balb/c mouse model. We have found that use of electroporation allows a single intramuscular (i.m.) DNA injection to be as effective as repeated i.m. DNA injections in activation of both Ag85A-specific CD4 and CD8 T cells. Co-expression of immune-enhancing cytokine GM-CSF by the same plasmid DNA TB vaccine could further enhance T cell activation including CTL activities on top of electroporation. With regard to immune protection from pulmonary M. tb challenge, use of electroporation also allows a single i.m. DNA injection to be as effective as repeated i.m. DNA injections. Co-expression of GM-CSF transgene also moderately enhances immune protection and such effect is more evident for systemic protection. However, GM-CSF expression has little added effect on immune protection by electroporation-aided immunization protocols. Our findings thus will help with the development of future DNA TB immunization strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052817     DOI: 10.1016/j.vaccine.2006.09.089

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Gene transfer: how can the biological barriers be overcome?

Authors:  Jean-Michel Escoffre; Justin Teissié; Marie-Pierre Rols
Journal:  J Membr Biol       Date:  2010-07-10       Impact factor: 1.843

Review 2.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

3.  Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.

Authors:  Daniel O Villarreal; Jewell Walters; Dominick J Laddy; Jian Yan; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Gene electrotransfer: from biophysical mechanisms to in vivo applications : Part 2 - In vivo developments and present clinical applications.

Authors:  Jean-Michel Escoffre; Chloé Mauroy; Thomas Portet; Luc Wasungu; Aurelie Paganin-Gioanni; Muriel Golzio; Justin Teissié; Marie-Pierre Rols
Journal:  Biophys Rev       Date:  2009-11-10

5.  Design and Construction of a Cloning Vector Containing the hspX Gene of Mycobacterium tuberculosis.

Authors:  Atieh Yaghoubi; Ehsan Aryan; Hosna Zare; Shadi Alami; Roghayeh Teimourpour; Zahra Meshkat
Journal:  Rep Biochem Mol Biol       Date:  2016-10

6.  Electroporation-mediated gene delivery.

Authors:  Jennifer L Young; David A Dean
Journal:  Adv Genet       Date:  2014-12-11       Impact factor: 1.944

7.  Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.

Authors:  Yao Ma; Huai-Jie An; Xiao-Qi Wei; Qing Xu; Yun-Zhou Yu; Zhi-Wei Sun
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

8.  Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis.

Authors:  A Francisco-Cruz; D Mata-Espinosa; S Estrada-Parra; Z Xing; R Hernández-Pando
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

9.  Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis.

Authors:  Jingyu Mu; Mangalakumari Jeyanathan; Cherrie-Lee Small; Xizhong Zhang; Elizabeth Roediger; Xueya Feng; Duncan Chong; Jack Gauldie; Zhou Xing
Journal:  Mol Ther       Date:  2009-03-24       Impact factor: 11.454

Review 10.  Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor.

Authors:  Alejandro Francisco-Cruz; Miguel Aguilar-Santelises; Octavio Ramos-Espinosa; Dulce Mata-Espinosa; Brenda Marquina-Castillo; Jorge Barrios-Payan; Rogelio Hernandez-Pando
Journal:  Med Oncol       Date:  2013-11-22       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.